![NMD Pharma on Twitter: "Dr @DaveArnoldLab, a professor at @OhioState and a close collaborator with #NMDPharma on both #CMT and #Sarcopenia observational studies is currently visiting the NMD Pharma team in #Aarhus. NMD Pharma on Twitter: "Dr @DaveArnoldLab, a professor at @OhioState and a close collaborator with #NMDPharma on both #CMT and #Sarcopenia observational studies is currently visiting the NMD Pharma team in #Aarhus.](https://pbs.twimg.com/media/FPKyo2zWYAMf0hD.jpg)
NMD Pharma on Twitter: "Dr @DaveArnoldLab, a professor at @OhioState and a close collaborator with #NMDPharma on both #CMT and #Sarcopenia observational studies is currently visiting the NMD Pharma team in #Aarhus.
![Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service](https://nordiclifescience.org/wp-content/public_html/2022/07/2021-03-08-NMD-2238-e1657558866597-760x380.jpg)
Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service
![Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service](https://nordiclifescience.org/wp-content/public_html/2022/07/2021-03-08-NMD-2179-e1657559167768.jpg)
Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service
![NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes](https://globalgenes.org/wp-content/uploads/2022/02/Thomas-Holm-Pedersen-NMD.jpg)
NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes
![NMD pulls in $40M from Jeito-led, Roche-backed syndicate, gaining financial muscle to crack myasthenia gravis market | Fierce Biotech NMD pulls in $40M from Jeito-led, Roche-backed syndicate, gaining financial muscle to crack myasthenia gravis market | Fierce Biotech](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1641490642/GettyImages-866149824%20%281%29.jpg/GettyImages-866149824%20%281%29.jpg?VersionId=lm.pi47bTRA.WNeogYiEG7XzDbOWaYme)
NMD pulls in $40M from Jeito-led, Roche-backed syndicate, gaining financial muscle to crack myasthenia gravis market | Fierce Biotech
![Jeito Capital Becomes Key Investor in NMD Pharma as Part of a €35 Million New Financing | Business Wire Jeito Capital Becomes Key Investor in NMD Pharma as Part of a €35 Million New Financing | Business Wire](https://mms.businesswire.com/media/20220214005583/en/1358538/22/JEITO-04_%281%29.jpg)